Breaking News, Financial News

Financial Report: Hospira 2Q

Specialty Injectables sales in the quarter were $574.4 million (+17%), driven by U.S. sales of generic oncolytic oxaliplatin and Precedex.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Hospira 2Q 2Q Revenues: $968.2 million (+1%) 2Q Earnings: $83.5 million (+227%) YTD Revenues: $2.0 billion (+9%) YTD Earnings: $225.2 million (+18%) Comments: Specialty Injectables sales in the quarter were $574.4 million (+17%), driven by U.S. sales of generic oncolytic oxaliplatin and Precedex. Other global Pharma revenues were $149.6 million (-16%). YTD Specialty Injectables sales were $1.2 billion (+29%). Other Pharma revenues were $295.7 million (-15%). Visit Hospira at Co...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters